Skip to main content
Premium Trial:

Request an Annual Quote

A New Team

Genentech and 23andMe are collaborating on a study to determine genetic influences on how breast cancer patients respond to bevacizumab, also known as Avastin, reports Erika Check Hayden at the Nature News blog. She adds that FDA recently revoked the approval for Avastin to be used to treat certain breast cancers. As our sister publication Pharmacogenomics Reporter noted at that time, Genentech said it was planning to conduct a clinical trial to find biomarkers that would identify breast cancer patients who would respond to the drug. Now, Genentech and 23andMe are recruiting people diagnosed with metastatic or recurrent breast cancer and who have been treated with bevacizumab for their new study. "23andMe has been increasingly turning towards research studies as consumer demand for its services has plateaued," Check Hayden adds.

The Scan

Rise of BA.5

The New York Times reports that the Omicron subvariant BA.5 has become the dominant version of SARS-CoV-2 in the US.

UK Health Secretary Resigns

Sajid Javid, the UK health secretary, resigned along with Chancellor Rishi Sunak, saying they cannot work with Prime Minister Boris Johnson's government, CNN reports.

Clones From Freeze-Dried Cells

A team in Japan has cloned mice from freeze-dried skin cells, according to the Guardian.

Genome Research Papers on Craniosynostosis, Macaque Retrotransposition, More

In Genome Research this week: structural variants in craniosynostosis, LINE-1 activity in rhesus macaque brain, and more.